COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

Regeneron Pharmaceuticals

Status and phase: Terminated; Phase 2

Conditions: COVID-19

Treatments: Drug: casirivimab+imdevimab

Study type: Interventional

Funder types: Industry

Identifiers

NCT04992273

2021-004590-30 (EudraCT Number)

R10933-10987-COV-2121

Details and patient eligibility

About

The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration

The secondary objectives of the study are:

• To assess the safety and tolerability of SC or single administration of casirivimab+imdevimab
• To assess the occurrence of grade ≥3 injection site reactions and grade ≥3 hypersensitivity reactions, in participants treated with SC doses of casirivimab+imdevimab
• To assess the immunogenicity of casirivimab+imdevimab

Enrollment: 7 patients

Sex: All

Ages: 1 minute to 12 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

1. Is <12 years of age and ≥3 kg to <40 kg at the time parental/guardian consent is signed

2. Has at least one risk factor for developing severe COVID-19 if they were to become infected, such as:

   1. Obesity (BMI [kg/m2] ≥95th percentile for age and sex based on CDC growth charts)
   2. Cardiovascular disease
   3. Chronic lung disease
   4. Type 1 or type 2 diabetes mellitus
   5. Chronic kidney disease, including those on dialysis
   6. Chronic liver disease
   7. Immunocompromised or immunodeficient, based on Investigator's assessment (examples include cancer treatment, bone marrow or organ transplantation, immune deficiencies, HIV infection, sickle cell anemia, thalassemia, and prolonged use of immune-weakening medications)
   8. Medical complexities (examples include any underlying genetic condition, neurologic condition, metabolic condition, or congenital heart disease)
   9. Any other condition deemed by the Investigator to be a risk factor for severe COVID-19

Key Exclusion Criteria:

1. Has positive diagnostic test for SARS-CoV-2 infection from a sample collected during screening ≤7 days prior to study drug administration Note: The sample for the test should be collected ≤7 days within study drug administration, and the result should be reviewed and confirmed negative prior to dosing. Historical records will not be accepted.
2. Has active respiratory or non-respiratory symptoms consistent with COVID-19 in the opinion of the Investigator
3. Has subject-reported clinical history of COVID-19, as determined by Investigator, within the last 90 days
4. Has subject-reported history of prior Emergency Use Authorization (EUA)/approved positive diagnostic test for SARSCoV-2 infection within the last 90 days
5. Is currently hospitalized or was hospitalized for >24 hours for any reason within 14 days of the screening visit
6. Prior use (within 90 days prior to study drug administration) or current use of any investigational, authorized, or approved passive antibody for prophylaxis of SARS-CoV-2 infection, including convalescent plasma, convalescent sera, hyperimmune globulin, or other monoclonal antibodies (eg, bamlanivimab and etesevimab, sotrovimab)
7. Has initiated vaccination for SARS-CoV-2 with an investigational or approved vaccine, but has not completed the vaccine schedule as recommended by the vaccine manufacturer.
8. Plans to receive an investigational or approved SARS-CoV-2 vaccine within 90 days after study drug administration, or per the recommended time frame from the current Centers for Disease Control vaccination guidelines (CDC, 2021b)

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 4 patient groups

≥20 kg to <40 kg

Experimental group

Description:

SC administration

Treatment:

Drug: casirivimab+imdevimab

≥10 kg to <20 kg

Experimental group

Description:

SC administration

Treatment:

Drug: casirivimab+imdevimab

≥5 kg to <10 kg

Experimental group

Description:

SC administration

Treatment:

Drug: casirivimab+imdevimab

≥3 kg to <5 kg

Experimental group

Description:

SC administration

Treatment:

Drug: casirivimab+imdevimab